ReviewJournal of pharmacy & bioallied sciences2025
Harnessing Artificial Intelligence in Drug Discovery: Transformative Approaches and Future Directions.
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug-disease interactions in inflammation: mechanisms, clinical Impact, and future directions.Inflammopharmacology · 2026Review
- Artificial Intelligence Applicability in the Pharmaceutical Industry: Present Perspectives and Future Formations.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most strategic weapon in drug discovery in the recent past has been artificial intelligence (AI)-bringing new approaches to one of the toughest areas of the pharmaceutical industry. Various AI approaches such as DL and ML methods utilized in various stages of drug discovery and development including but not limited to virtual screening and target identification are also discussed here. Employing this approach, this review looks at AI programs and platforms that exist in drug discovery today in a bid to outline what a future with AI in this field has in stock. In addition to this, this review does not only give a momentary state of the state of affairs of the AI in the space, but also briefly discusses what is in store next, along with the drawback and the opportunity more so from this perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.